Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma

Fengyan Jin, Peiyu Yang, Haimin Chen, Xinyue Liang, Weiling Xu, Shanshan Yu, Wenyang Huang, Xingchen Yi, Qiang Guo, Mengru Tian, Tingting Yue, Mengyao Li, Yingjie Zhang, Mengxue Zhang, Yurong Yan, Zhongli Hu, Shaji K Kumar, Fan Zhou, Yun Dai

Blood (2022) 140 (Supplement 1): 4360–4361.

https://doi.org/10.1182/blood-2022-168602

Published: 2022

Journal Articles

TET2 Down-Regulation Confers Bortezomib Resistance in Multiple Myeloma

Yun Dai, Xiaobo Liu, Ting Yang, Shaji K Kumar, Fengyan Jin

Blood (2022) 140 (Supplement 1): 4185–4186.

https://doi.org/10.1182/blood-2022-168239

Published: 2022

Journal Articles

IRF4 Is Reciprocally Dysregulated Via NF-Κb-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma

Yun Dai, MD, Yue Sun, MS, Shaji K. Kumar, MD, Wei Wu, MD, Fengyan Jin, MD PhD

Blood (2019) 134 (Supplement_1): 687.

https://doi.org/10.1182/blood-2019-132051

Published: 2019

Journal Articles

A Multi-Center Epidemiological and Prognostic Analysis of Cytogenetic Abnormalities in a Cohort of 1015 Chinese Patients with Newly-Diagnosed Multiple Myeloma

Fengyan Jin, MD PhD, Guangxun Gao, MD, Yujun Dong, MD, Chunrui Li, MD PhD, Wenrong Huang, Limo Zhang, MD, Qiang Zhu, MD, Ruifeng Yuan, MD, Li Xu, MD, Yanjie Xu, MD, Qian Xu, Shaji K. Kumar, MD, Yun Dai, MD

Blood (2019) 134 (Supplement_1): 3094.

https://doi.org/10.1182/blood-2019-132076

Published: 2019

Journal Articles

Apatinib Exhibits Cytotoxicity to Acute Myeloid Leukemia Cell Via Targeting VEGFR2-Mediated Pro-Survival Signaling and Angiogenesis

Lian Yu, Manman Deng, Zhifeng Li, Zhihong Fang, Yun Dai, MD, Bing Xu

Blood (2019) 134 (Supplement_1): 5158.

https://doi.org/10.1182/blood-2019-123472

Published: 2019

Journal Articles

The Lysine-Specific Demethylase KDM4A/JMJD2A Acts As a Tumor Suppressor in Multiple Myeloma

Fengyan Jin, MDPhD, Shaji K. Kumar, MD, Yun Dai, MD

Blood (2018) 132 (Supplement 1): 191.

https://doi.org/10.1182/blood-2018-191

Published: 2018

Journal Articles

Targeting the NF-κb-Dependent HIF-1β Pathway Reprograms Macrophage Polarization Induced By Oxidized LDL

Jin Fengyan, Wang Xue, Wu Jiang, Yun Dai, MD

Blood (2017) 130 (Supplement 1): 993.

https://doi.org/10.1182/blood.V130.Suppl_1.993.993

Published: 2017

Journal Articles

Alvocidib Enhances Venetoclax Sensitivity in Unfavorable-Risk Multiple Myeloma Cells In Vitro and In Vivo

Liang Zhou, PhD, Yu Zhang, PhD, Deepak Sampath, PhD, Joel D. Leverson, PhD, Yun Dai, MD, Maciej Kmieciak, Matthew Nguyen, Robert Z. Orlowski, MD PhD, Steven Grant, MD

Blood (2017) 130 (Supplement 1): 2540.

https://doi.org/10.1182/blood.V130.Suppl_1.2540.2540

Published: 2017

Journal Articles

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Joel G Turner, PhD, Trinayan Kashyap, MS, Jana L Dawson, BS, Juan A Gomez, BS, Alexis Bauer, BS, Steven Grant, MD, Yun Dai, PhD, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Yosef Landesman, PhD, Daniel M Sullivan, MD

Blood (2016) 128 (22): 3299.

https://doi.org/10.1182/blood.V128.22.3299.3299

Published: 2016

Journal Articles

Clarithromycin Interacts with Lenalidomide in the Combination Regimen Bird and Overcomes Drug Resistance in Multiple Myeloma

Fengyan Jin, MD PhD, Shuang Li, MD, Lijuan Chen, PhD, Chuan Wu, MD, Wei Li, MD, Jian Hou, MD, Yun Dai, MD PhD

Blood (2016) 128 (22): 2125.

https://doi.org/10.1182/blood.V128.22.2125.2125

Published: 2016

Journal Articles

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

Liang Zhou, Shuang Chen, Yu Zhang, Maciej Kmieciak, Yun Leng, Lihong Li, Hui Lin, Kathryn A. Rizzo, Catherine I. Dumur, Andrea Ferreira-Gonzalez, Mohamed Rahmani, Lawrence Povirk, Sri Chalasani, Allison J. Berger, Yun Dai, Steven Grant

Blood (2016) 127 (18): 2219–2230.

https://doi.org/10.1182/blood-2015-06-653717

Published: 2016

Includes: Supplemental data

Journal Articles

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Daniel M Sullivan, MD, Trinayan Kashyap, MS, Jana L Dawson, BS, Yosef Landesman, PhD, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, PhD, Michael Kauffman, MD PhD, Sharon Shacham, Joel G Turner, PhD

Blood (2015) 126 (23): 3048.

https://doi.org/10.1182/blood.V126.23.3048.3048

Published: 2015

Journal Articles

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Christopher L Cubitt, PhD, Erkan Baluglo, PhD, Steven Grant, MD, Yun Dai, PhD, Kenneth H Shain, MD PhD, William S. Dalton, PhD MD, Sharon Shacham, William Senapedis, PhD, Daniel M Sullivan, MD

Blood (2015) 126 (23): 1818.

https://doi.org/10.1182/blood.V126.23.1818.1818

Published: 2015

Journal Articles

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, MD PhD, Chris Cubitt, PhD, Rachid Baz, MD, Taiga Nishihori, MD, Michael Kauffman, MD PhD, Sharon Shacham, PhD MBA, Daniel M Sullivan, MD

Blood (2014) 124 (21): 2084.

https://doi.org/10.1182/blood.V124.21.2084.2084

Published: 2014

Journal Articles

HDAC Inhibitors Reciprocally Interacts the Wee1 Inhibitor AZD1775 to Abrogate Both the G1/S and G2/M Checkpoints Via Chk1-Related cdc2/Cdk1 Threonine 14 Dephosphorylation in AML Cells

Yun Dai, MD PhD, Liang Zhou, MDPhD, Yu Zhang, PhD, Shuang Chen, MD PhD, Maciej Kmieciak, PhD, Yun Leng, MD, Lin Hui, MD, Steven Grant, MD

Blood (2014) 124 (21): 997.

https://doi.org/10.1182/blood.V124.21.997.997

Published: 2014

Journal Articles

Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism

Xin-Yan Pei, MD, Michael W Sanderson, BS, Leena E Youssefian, M.S, Jessica Felthousen, BS, Lora B Kramer, BS, Yun Dai, PhD, Steven Grant, MD

Blood (2014) 124 (21): 4763.

https://doi.org/10.1182/blood.V124.21.4763.4763

Published: 2014

Journal Articles

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis

Shuang Chen, Yu Zhang, Liang Zhou, Yun Leng, Hui Lin, Maciej Kmieciak, Xin-Yan Pei, Richard Jones, Robert Z. Orlowski, Yun Dai, Steven Grant

Blood (2014) 124 (17): 2687–2697.

https://doi.org/10.1182/blood-2014-03-564534

Published: 2014

Includes: Supplemental data

Journal Articles

Bim-Targeting Therapy Circumvents Adaptive Bortezomib-Resistance In Myeloma Through a Novel Cross-Link Between Autophagy and Apoptosis

Shuang Chen, MD/PhD, Yun Dai, MD, PhD, Yu Zhang, PhD, Liang Zhou, MD/PhD, Hui Lin, MD, Xin-Yan Pei, Robert Z. Orlowski, M.D., Ph.D., Steven Grant, MD

Blood (2013) 122 (21): 601.

https://doi.org/10.1182/blood.V122.21.601.601

Published: 2013

Journal Articles

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

Jolanta Skalska, PhD, Michelle M. Kiebala, PhD, Shannon P. Hilchey, PhD, Yun Dai, MD, PhD, Steven Grant, MD, Paul S. Brookes, PhD, Derick R. Peterson, PhD, Sanjay B. Maggirwar, PhD, Steven H. Bernstein, MD

Blood (2012) 120 (21): 1658.

https://doi.org/10.1182/blood.V120.21.1658.1658

Published: 2012

Journal Articles

Cytokinetically quiescent (G 0 /G 1 ) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2

Xin-Yan Pei, Yun Dai, Leena E. Youssefian, Shuang Chen, Wesley W. Bodie, Yukie Takabatake, Jessica Felthousen, Jorge A. Almenara, Lora B. Kramer, Paul Dent, Steven Grant

Blood (2011) 118 (19): 5189–5200.

https://doi.org/10.1182/blood-2011-02-339432

Published: 2011

Includes: Supplemental data

NARROW

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma

TET2 Down-Regulation Confers Bortezomib Resistance in Multiple Myeloma

IRF4 Is Reciprocally Dysregulated Via NF-Κb-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma

A Multi-Center Epidemiological and Prognostic Analysis of Cytogenetic Abnormalities in a Cohort of 1015 Chinese Patients with Newly-Diagnosed Multiple Myeloma

Apatinib Exhibits Cytotoxicity to Acute Myeloid Leukemia Cell Via Targeting VEGFR2-Mediated Pro-Survival Signaling and Angiogenesis

The Lysine-Specific Demethylase KDM4A/JMJD2A Acts As a Tumor Suppressor in Multiple Myeloma

Targeting the NF-κb-Dependent HIF-1β Pathway Reprograms Macrophage Polarization Induced By Oxidized LDL

Alvocidib Enhances Venetoclax Sensitivity in Unfavorable-Risk Multiple Myeloma Cells In Vitro and In Vivo

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Clarithromycin Interacts with Lenalidomide in the Combination Regimen Bird and Overcomes Drug Resistance in Multiple Myeloma

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

HDAC Inhibitors Reciprocally Interacts the Wee1 Inhibitor AZD1775 to Abrogate Both the G1/S and G2/M Checkpoints Via Chk1-Related cdc2/Cdk1 Threonine 14 Dephosphorylation in AML Cells

Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis

Bim-Targeting Therapy Circumvents Adaptive Bortezomib-Resistance In Myeloma Through a Novel Cross-Link Between Autophagy and Apoptosis

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

Cytokinetically quiescent (G 0 /G 1 ) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only